Mohamed N. Elshabrawi

Dr. Mohamed N. Elshabrawi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
BHBara M. Hammadeh
Bara M. Hammadeh
AAAbdullah Yousef Aldalati
Abdullah Yousef Aldalati
AMAlzahra'a Al Matairi
Alzahra'a Al Matairi
Mohamed N. ElshabrawiMohamed N. Elshabrawi
Mohamed N. Elshabrawi
FQFares Amer Qtaishat
Fares Amer Qtaishat
FAFawzi Abuhijla
Fawzi Abuhijla

14 May 2025 in Indian Journal of Anaesthesia
Verified
Journal Article
Open access
LSLaila Shalabi
Laila Shalabi
AIAhmed Ibrahim
Ahmed Ibrahim
MEMohamed Adel Elsawy
Mohamed Adel Elsawy
SZSofian Zreigh
Sofian Zreigh
MDMuhiddin Dervis
Muhiddin Dervis
Mohamed Tarek AbuelazmMohamed Tarek Abuelazm
Mohamed Tarek Abuelazm
Background and Aims: Cardiac surgeries often lead to postoperative complications, which affect recovery and increase morbidity and mortality. This systematic review aims to assess L-carnitine’s effect on preventing postoperative complications across various cardiac surgeries, addressing gaps in current literature on its potential therapeutic benefits. Methods: We systematically searched Web of Science, Cochrane, Embase, PubMed, and Scopus databases until March 2025. Statistical analysis was performed using R version 4.3.2. Effect sizes were measured with relative risks (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes, while heterogeneity was evaluated using the I² statistic. Results: Thirteen randomised controlled trials(RCTs) with 786 patients were included. L-carnitine significantly increased the cardiac index (CI) (MD: 0.14; 95% CI: 0.07, 0.20; P < 0.01) and left ventricular stroke work index (LVSWI) (MD: 0.42; 95% CI: 0.06, 0.78; P = 0.02). In addition, L-carnitine significantly improved the left ventricular ejection fraction (LVEF) (MD: 7.88; 95% CI: 6.67, 9.09; P < 0.01), with a significant reduction in postoperative atrial fibrillation (POAF) (RR: 0.53; 95% CI: 0.30, 0.95; P = 0.03). In contrast, there was no significant reduction in in-hospital mortality (RR: 0.51; 95% CI: 0.10, 2.63; P = 1.00) and stroke incidence (RR: 0.85; 95% CI: 0.12, 5.76; P = 0.82). Conclusion: Preoperative administration of L-carnitine demonstrates meaningful short-term benefits in enhancing CI, LVSWI, and LVEF while reducing the incidence of POAF following cardiac surgery. These findings suggest a potential role for L-carnitine supplementation in optimising perioperative cardiac care, enhancing recovery, and reducing complications following cardiac surgery. However, the existing studies are limited in scope, making it challenging to draw robust conclusions.

Verified
Journal Article
Open access
PDF file
KMKareem A. Mohamed
Kareem A. Mohamed
Mohamed N. ElshabrawiMohamed N. Elshabrawi
Mohamed N. Elshabrawi
HMHossam Albeyoumi Mohammed
Hossam Albeyoumi Mohammed
MKMohamed Khalil
Mohamed Khalil
AAAhmed AlGhazawy
Ahmed AlGhazawy
Akshay KumarAkshay Kumar
Akshay Kumar
Background: Resistant hypertension represents a significant clinical challenge, often driven by dysregulated aldosterone production. Aldosterone synthase inhibitors (ASIs) are a novel therapeutic class designed to directly suppress aldosterone biosynthesis. This study aimed to synthesize evidence regarding the comparative efficacy, optimal dosing, and dose–response relationships of three ASIs—baxdrostat, lorundrostat, and osilodrostat—for the treatment of resistant hypertension. Methods: A systematic review and network meta-analysis (NMA) were conducted following PRISMA 2020 guidelines. We searched PubMed, Web of Science, and CENTRAL for randomized controlled trials (RCTs) published up to 31 October 2025. The primary outcome was the mean change in systolic blood pressure (SBP) compared to placebo. We utilized a frequentist random-effects model, characterized dose–response relationships via meta-regression, and ranked treatments using the Surface Under the Cumulative Ranking Curve (SUCRA). Results: The analysis included 8 RCTs comprising 3253 participants. Baxdrostat 2 mg once daily demonstrated the greatest antihypertensive efficacy with a mean SBP reduction of −13.8 mmHg (95% CI: −17.5 to −10.1) versus placebo, followed by Lorundrostat 100 mg (−12.5 mmHg) and Baxdrostat 1 mg (−11.5 mmHg). SUCRA analysis identified Baxdrostat as the highest-ranked treatment (83.0%), followed by Lorundrostat (67.8%) and Osilodrostat (55.5%). Dose–response meta-regression revealed strong linear correlations for Baxdrostat (R2 = 0.91), Osilodrostat (R2 = 0.81), and Lorundrostat (R2 = 0.80). Conclusions: ASIs, particularly Baxdrostat and Lorundrostat, offer robust blood pressure reductions in patients with resistant hypertension. The strong linear dose–response relationships suggest these agents have a favorable therapeutic window for titration. While effective, clinical implementation requires careful monitoring for adverse events.

25 September 2026 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
HSHasnain Wajeeh Saqib
Hasnain Wajeeh Saqib
Mohamed N. ElshabrawiMohamed N. Elshabrawi
Mohamed N. Elshabrawi
ABArpitha Sirichandana Baggu
Arpitha Sirichandana Baggu
VPVikramjit Purewal
Vikramjit Purewal
SMShaiza Maryam
Shaiza Maryam
UKUtkarsh Kohli
Utkarsh Kohli

Verified
Journal Article
Open access
PDF file
DPDhruv Patel
Dhruv Patel
Mohamed N. ElshabrawiMohamed N. Elshabrawi
Mohamed N. Elshabrawi
Mohamed RahoumaMohamed Rahouma
Mohamed Rahouma
Akshay KumarAkshay Kumar
Akshay Kumar
Once considered a surgical frontier fraught with risk, aortic arch aneurysms now represent a domain of evolving innovation. Despite their rarity, they pose severe risks of dissection, rupture, and mortality if not adequately managed. Primarily caused by prior aortic dissections, atherosclerosis, or connective tissue disorders, these aneurysms are often found incidentally on CTA or MRA imaging. Medical management focuses on reducing aortic wall stress through blood pressure control, risk factor modification, and regular imaging to monitor growth. Surgical intervention is typically indicated when the aneurysm diameter exceeds 5.5 cm, exhibits rapid growth, or causes symptoms such as compression or dissection. Open repair remains the gold standard for treatment due to its superior long-term outcomes, though hybrid and endovascular approaches are favored for high-risk patients due to reduced perioperative morbidity. Innovations in hybrid techniques and endovascular devices, alongside advancements in cerebral perfusion strategies, are shaping the future of personalized and minimally invasive approaches to aortic arch repair. This comprehensive review delves into the current management strategies for these aneurysms.

18 September 2026 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
FAFaizan Ahmed
Faizan Ahmed
AZAyehsa Zulfiqar
Ayehsa Zulfiqar
Mohamed N. ElshabrawiMohamed N. Elshabrawi
Mohamed N. Elshabrawi
OAOmama Ayatullah
Omama Ayatullah
SQSheraz Qasim
Sheraz Qasim
KAkhurram arshad
khurram arshad
Introduction: Atrial fibrillation (AF) is highly prevalent in heart failure (HF) and is linked to increased mortality and hospitalization in both preserved (HFpEF) and reduced ejection fraction (HFrEF). Catheter ablation (CA) has emerged as an effective rhythm-control strategy beyond medical therapy (MT), but phenotype-specific differences remain unclear. We compared the efficacy and safety of CA versus MT in AF with HFpEF or HFrEF. Methods: PubMed, Embase, Scopus, and Cochrane databases were searched through December 2025. Random-effects meta-analyses were conducted in R (version 4.5.3), reporting risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs). Results: Fifteen studies involving 27,130 patients (CA: 13,579; MT: 13,551) were included. Catheter ablation significantly reduced overall all-cause mortality (RR 0.44), with a significant benefit in HFpEF (RR 0.44), whereas the reduction in HFrEF did not reach statistical significance (RR 0.53, 95% CI 0.21–1.38). Cardiovascular mortality and cardiovascular hospitalization were also reduced overall, without significant differences between HF phenotypes. Stroke and atrial arrhythmia recurrence were not significantly reduced in the primary analyses, and favorable findings observed in sensitivity analyses were considered exploratory . Catheter ablation significantly improved LVEF in HFrEF but not in HFpEF, while effects on exercise capacity and biomarkers varied across outcomes and phenotypes. Adverse events were comparable between treatment strategies. Conclusion: Catheter ablation was associated with favorable clinical outcomes compared with medical therapy in AF with HF; however, the magnitude and statistical certainty of benefit varied across heart failure phenotypes and outcomes.